Wolfe Research Upgrades Repligen (NASDAQ:RGEN) to “Outperform”

Repligen (NASDAQ:RGEN) was upgraded by research analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a report released on Tuesday, MarketBeat reports. The firm presently has a $160.00 target price on the biotechnology company’s stock. Wolfe Research’s price target would suggest a potential upside of 15.95% from the stock’s current price.

A number of other brokerages also recently issued reports on RGEN. Evercore ISI started coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price target for the company. Canaccord Genuity Group lowered their target price on shares of Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a research note on Wednesday, April 16th. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Monday. TD Cowen began coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective for the company. Finally, Royal Bank of Canada raised their target price on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research report on Friday, February 21st. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.25.

Repligen Stock Down 1.0 %

NASDAQ:RGEN opened at $137.99 on Tuesday. Repligen has a 52 week low of $102.97 and a 52 week high of $182.52. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock’s fifty day moving average is $138.77 and its two-hundred day moving average is $145.87. The stock has a market capitalization of $7.75 billion, a price-to-earnings ratio of -270.57, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to analysts’ expectations of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Repligen’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period last year, the business posted $0.28 EPS. Research analysts anticipate that Repligen will post 1.72 EPS for the current year.

Insider Buying and Selling

In other news, Director Margaret Pax acquired 250 shares of the business’s stock in a transaction on Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the transaction, the director now owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. UMB Bank n.a. boosted its holdings in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in Repligen during the fourth quarter worth $216,000. Van ECK Associates Corp lifted its holdings in Repligen by 7.8% in the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock valued at $6,078,000 after acquiring an additional 3,066 shares during the period. Stephens Investment Management Group LLC lifted its holdings in Repligen by 7.4% in the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock valued at $77,267,000 after acquiring an additional 37,057 shares during the period. Finally, Artemis Investment Management LLP grew its stake in shares of Repligen by 18.4% during the 4th quarter. Artemis Investment Management LLP now owns 153,832 shares of the biotechnology company’s stock worth $22,143,000 after purchasing an additional 23,905 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.